Trials / Completed
CompletedNCT05601310
Metabolic Characteristics of Type 2 Diabetes Mellitus Combined With Acute Myocardial Infarction: A Untargeted Metabolomics Study
12,13-DHOME and Noradrenaline Are Associated With Occurrence of Acute Myocardial Infarction in Patients With Type 2 Diabetes Mellitus: A Untargeted Metabolomics Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 82 (actual)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a retrospective case-control study. In this study, through untargeted metabolomics, investigators identified several specific changed serum metabolites in T2DM patients with or without AMI and their functions/category. Moreover, researchers selected several endogenous candidate biomarkers with larger fold change for validation in expanded population to find biomarkers which effectively predict the development of STEMI in patients with T2DM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | liquid chromatography-mass spectrometry (LC/MS) analysis | To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards. |
Timeline
- Start date
- 2017-05-23
- Primary completion
- 2020-05-28
- Completion
- 2020-05-28
- First posted
- 2022-11-01
- Last updated
- 2022-11-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05601310. Inclusion in this directory is not an endorsement.